Copyright
©The Author(s) 2023.
World J Cardiol. Apr 26, 2023; 15(4): 165-173
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.165
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.165
Variable | All patients | RVDD (No. 34) | No RVDD (No. 27) | P value |
Clinical data | ||||
Age (yr), mean ± SD | 54.3 ± 10.3 | 53.8 ± 9.7 | 52.9 ± 11 | 0.735 |
Gender, M/F | 45/16 (74/26) | 28/6 (82/18) | 17/10 (63/37) | 0.087 |
BMI (kg/m2), mean ± SD | 32.9 ± 5.3 | 32.4 ± 5.6 | 32.7 ± 4.9 | 0.836 |
Charlson index, median (IQR) | 2.0 (1.0-3.0) | 2.0 (1.0-3.0) | 2.0 (1.0-3.0) | 0.772 |
Transferred from peripheral hospitals | 38 (62) | 18 (52) | 20 (74) | 0.9 |
Time from symptoms’ onset to ICU (d), median (IQR) | 13 (10-13) | 9 (8-12) | 12 (10-14) | 0.075 |
SOFA, median (IQR) | 8.0 (7.0-10.0) | 10 (8-10) | 7 (6-10) | 0.029 |
Mechanical ventilation length to ECMO support (d), median (IQR) | 6.0 (8.0-11.0) | 8.5 (6-12) | 7 (4-10) | 0.046 |
ECMO duration (d), median (IQR) | 22 (13-42) | 24.5 (9-44) | 21 (15-35) | 0.765 |
Renal replacement therapy | 29 (48) | 22 (65) | 7 (26) | 0.002 |
ICU death | 33 (54.1) | 21 (62) | 12 (44) | 0.024 |
Biohumoral data | ||||
Creatinine (mg/dL), median (IQR) | 1.00 (0.72-1.86) | 0.83 (0.61-1.34) | 1.65 (0.78-2.00) | 0.025 |
D-dimer (ng/mL), median (IQR) | 3594 (2252-7214) | 3748 (1740-12085) | 3550 (2368-5007) | 0.425 |
CRP (mg/dL), median (IQR) | 142 (88-144) | 121 (87-174) | 165 (98-212) | 0.55 |
IL-6 (pg/mL), median (IQR) | 34 (7.4-70.0) | 45 (6.9-105.0) | 34 (21-58.0) | 0.772 |
Troponin (pg/mL), median (IQR) | 21 (14.0-38.0) | 33.0 (14.0-112.0) | 21.0 (8.5-48.0) | 0.253 |
NT-pro BNP (pg/mL), median (IQR) | 874 (345-1654) | 735 (252-1467) | 1273 (585-1868) | 0.058 |
LDH IU/L, median (IQR) | 465 (375-538) | 421 (363-510) | 473 (424-542) | 0.078 |
Echocardiographic data | ||||
LVEF (%), mean ± SD | 63.9 ± 7.6 | 64.3 ± 7.9 | 64.5 ± 7.5 | 0.113 |
RV/LV, mean ± SD | 0.58 ± 0.17 | 0.69 ± 0.08 | 0.45 ± 0.14 | 0.0001 |
TAPSE (mm), mean ± SD | 18.0 (10.0-21.0) | 13.9 (10.0 ± 14.5) | 17.4 (16.0-22.5) | 0.015 |
sPAP (mmHg), mean ± SD | 58.4 ± 9.4 | 64 ± 11 | 59.1 ± 7.7 | 0.015 |
e/e1 | 11 ± 3 | 12 ± 3 | 9 ± 3 | 0.0003 |
TAPSE/sPAP (mm/mmHg), mean ± SD | 0.28 ± 0.13 | 0.19 ± 0.10 | 0.28 ± 0.11 | 0.001 |
Ventilatory parameters | ||||
PEEP (cm H2O), mean ± SD | 12.2 ± 2.3 | 12.4 ± -2.4 | 12.1 ± 2.6 | 0.64 |
PO2/FiO2, mean ± SD | 62 (50-88) | 66 (54-88) | 60 (50-88) | 0.442 |
Norepinephrine, mean ± SD | 0.34 ± 0.22 | 0.39 ± 0.26 | 0.24 ± 0.10 | 0.011 |
- Citation: Lazzeri C, Bonizzoli M, Batacchi S, Cianchi G, Franci A, Socci F, Chiostri M, Peris A. Right ventricle dysfunction does not predict mortality in patients with SARS-CoV-2-related acute respiratory distress syndrome on extracorporeal membrane oxygenation support. World J Cardiol 2023; 15(4): 165-173
- URL: https://www.wjgnet.com/1949-8462/full/v15/i4/165.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i4.165